Premium
Tissue reactivity of anti‐Leu19
Author(s) -
FISCHLER D.F.,
BAUER T.W.,
TUBBS R.R.
Publication year - 1992
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.1992.tb00445.x
Subject(s) - pathology , monoclonal antibody , immunohistochemistry , histopathology , monoclonal , natural killer cell , biology , cell , medicine , antibody , immunology , cytotoxicity , in vitro , biochemistry , genetics
Monoclonal antibody anti‐Leu19, is a marker of natural killer cells. Since reactivity between anti‐Leu7, another natural killer cell marker, and small cell neuroendocrine carcinomas has been described, we evaluated the reactivity of anti‐Leu19 in 92 neuroendocrine tumours. Frozen sections in each case were immunostained using the avidin‐biotin‐peroxidase complex method with monoclonal anti‐Leu19. We found Leu19 expression in 93% of the cases. We also evaluated 149 other tumours, including adenocarcinomas, undifferentiated large cell carcinomas, lymphomas, melanomas and soft tissue tumours. We found Leu19 expression in 36% (by liberal interpretative criteria), or 29% (by conservative interpretative criteria) of these cases. Thus, while anti‐Leu19 appears to be a sensitive marker for neuroendocrine tumours, a lack of specificity limits its practical application in diagnostic histopathology.